

Temporal trends of hepatitis C virus transmission in internally displaced people who inject drugs in Odessa, Ukraine

Authors

Anna Yakovleva^{1,*}, Ganna Kovalenko^{2,3,*}, Matthew Redlinger³, Pavlo Smyrnov⁴, Olga Tymets⁴, Ania Korobchuk⁴, Lyudmyla Kotlyk⁵, Ganna Kolodyazeva⁵, Ganna Podolina⁵, Svetlana Chernyavskaya⁵, Steffanie A. Strathdee⁶, Samuel R Friedman⁷, Ian Goodfellow², Joel O. Wertheim⁶, Eric Bortz³, Luke Meredith², Tetyana I Vasylyeva⁶

* Authors contributed equally.

Affiliations

1. Medical Sciences Division, University of Oxford, Oxford, UK
2. Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK
3. Department of Biological Sciences, University of Alaska Anchorage, AK, USA
4. Alliance for Public Health, Kyiv, Ukraine
5. Odessa Regional Virology Laboratory, Odessa, Ukraine
6. Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA
7. Department of Population Health, NYU Grossman School of Medicine, NY, USA

Corresponding Author:

Dr Tetyana Vasylyeva tvasylyeva@health.ucsd.edu

Abstract

Background

Due to practical challenges associated with genetic sequencing in low resource environments, the burden of hepatitis C virus (HCV) in forcibly displaced people is understudied. We examined the use of field-applicable HCV sequencing methods and phylogenetic analysis to determine HCV transmission dynamics in internally displaced people who inject drugs (IDPWID) due to war in eastern Ukraine.

Methods

In this cross-sectional study, we used modified respondent-driven sampling to recruit IDPWID who have settled in Odessa, Ukraine. We generated partial and near full length genome (NFLG) HCV sequences using Oxford Nanopore MinION in a simulated field environment. Maximum likelihood and Bayesian methods were used to establish phylodynamic relationships.

Findings

Between June and September 2020, we collected epidemiological data and whole blood samples from 164 IDPWID. Rapid testing identified an HIV, anti-HCV, and HIV/HCV co-infection prevalence of 39%, 67.7%, and 31.1%, respectively. We generated 57 partial or NFLG HCV sequences and identified eight transmission clusters, of which at least two originated within a year and a half post-migration. Unstable housing post-migration was associated with more reports of injection drug use in the past 30 days ($p=0.048$).

Interpretation

Local generation of viral sequencing data and phylogenetic analysis in rapidly changing low-resource environments, such as those faced by forcibly displaced people, can inform timely adaptation of prevention and treatment.

Funding

Oxford University John Fell Fund, ISS Wellcome Trust, Branco Weiss Fellowship.

Background

Globally, 82.4 million people have been forcibly displaced following economic, political, and climate instability, which is almost twice as high as two decades earlier [1]. By 2050, a further 143 million people may become internally displaced because of climate change [2]. Internally displaced persons (IDPs, people who do not cross international borders) constitute the majority of forcibly displaced people: currently, there are 48 million IDPs residing in low- and middle-income countries, 85% of whom have been displaced due to conflict and violence [1].

Forced migration is associated with worse health outcomes in migrant compared to the autochthonous population, attributed to increased vulnerabilities and hardships experienced throughout the migration process, which are reinforced by structural inequalities, discrimination, and gender-based violence [3]. The burden of otherwise preventable and controllable infectious diseases is often high amongst IDPs, due at least in part to the collapse of local health systems and infrastructure [4].

Unstable housing post-migration, which broadly encompasses settlement in refugee camps, homelessness, residing in overcrowded homes, as well as with friends and relatives, has been implicated in increased risk of acquiring infections such as HIV post-migration [5]. This relationship is likely to be similar for hepatitis C virus (HCV) infections and might be exacerbated by risk factors such as injection drug use (IDU) [6].

As of 2021, Ukraine has the largest IDPs population in Europe: over 1.4 million people have been internally displaced and over 14,000 killed since the beginning of the war in the Donbass region (which includes Donetsk and Lugansk administrative regions) in eastern Ukraine and the annexation of Crimea in 2014 [7]; 38,600 of IDPs settled in Odessa in southern Ukraine. Concurrently, Ukraine has a high prevalence of IDU, which has caused the second largest HCV epidemic in Europe, following the Russian Federation [8, 9]. National HCV seroprevalence in PWID is 56%: lower amongst PWID in Odessa (47.5%) and Crimea (25.7% – 50.1%) compared to Donetsk (55.2%) and Lugansk (58.4%) [10]. In 2020, national HCV treatment uptake had risen modestly from 0.11% in 2013 to 6.5% in 2020 – an important step towards HCV elimination

since treatment can successfully cure the disease in >80% of cases [11] - but only 10-20% of those treated were PWID [12]. Although no data on HCV epidemiology in Ukrainian internally displaced PWID (IDPWID) is currently available, IDPs are likely to experience additional barriers in accessing appropriate interventions and treatment options compared to non-displaced populations [4].

Molecular epidemiology, the study of how epidemiological and evolutionary factors shape viral phylogenies [13], is increasingly utilised in public health settings due to the widespread availability of pathogen genetic sequences and has been used to identify HCV transmission clusters, thus improving our understanding of infection transmission chains [14, 15]. We previously used molecular epidemiology methods to show that internal displacement following war in eastern Ukraine triggered a geographic redistribution of existing HIV infections: migration from high prevalence regions in the east to lower prevalence regions in the west [16]. Similar analyses were not possible for HCV due to a lack of available genetic sequence data, despite Ukraine having one of the highest HCV burdens in the world [9].

Global efforts to reinforce molecular epidemiology-based surveillance of chronic viral infections, such as HIV and HCV, in the context of forced migration are hindered by the scarcity of available pathogen sequencing data, primarily due to practical laboratory limitations concerning hard to reach mobile populations. Recent advances in portable molecular biology tools applicable in low-resource environments, such as Nanopore® sequencing technology, have enabled molecular epidemiological characterisation of other viral pathogens such as Ebola and rabies in the field [17, 18]. Here we demonstrate Nanopore based partial and near full length genome (NFLG) sequencing of HCV clinical samples, which is directly applicable to sequencing in the field. We analysed locally generated sequencing data using phylogenetics to describe HCV transmission dynamics in IDPWID residing in Odessa, Ukraine. By combining our findings with epidemiological data, we reveal opportunities for improved targeting of local preventative interventions and infection management strategies. Overall, this work expands the potential of molecular epidemiology to the study of the burden of HCV in low-resource and rapidly changing environments, such as those faced by forcibly displaced people.

Methods

Study design and participants

This study was approved by the University of Oxford Tropical Research Ethical Committee (Reference: 530-20). Written informed consent was obtained from all participants. We used modified respondent-driven sampling (RDS) technique [19] to recruit IDPWID in Odessa, Ukraine, in June through September 2020. We started recruitment with four index cases, who were defined as people who 1) reported IDU in the last 30 days, 2) were internally displaced from Donetsk, Lugansk regions or Crimea because of the military conflict irrespective of their nationality, 3) were living with HIV, but were not receiving ART treatment at the time of study enrolment (Figure 1); and 4) were at least 18 years old. All participants who tested positive for HIV during the study were counselled by trained healthcare workers and linked to care. Unlike in the classic RDS approach, the number of distributed coupons differed depending on the HIV status of a participant: the index cases were given eight coupons to recruit other IDPs with history of IDU (not necessarily recent IDU experience); HIV-positive network members who were not in treatment at the time of the interview were offered up to eight coupons to recruit other IDPWID; HIV-positive IDPWID receiving ART and HIV-negative network members were offered three coupons to recruit other IDPWID. Upon recruitment, participants were briefly interviewed about their socio-demographic characteristics and their migration experience. Recruitment was terminated after the field study period of two months was completed.

Data Collection

All participants were interviewed about their migration history (e.g. region of origin, date of displacement, date of arrival to Odessa), their socio-demographic and housing information, and then were screened for HIV and HCV by rapid tests (Supplementary Methods). Whole blood samples were collected from all participants, and serum was isolated at the Odessa Regional Virology Laboratory and stored at -80°C .

Statistical analysis

We used chi-square tests to investigate whether participants' recent injection drug use, HIV and HCV status were significantly associated with their housing status

(Supplementary Table 3). We defined current IDU status as IDU in the last 30 days (yes/no). The result of rapid HIV and HCV test performed in this study was used to define HIV and HCV status. We dichotomized the housing status into stable and unstable. We defined stable housing as living in own house or flat, living with relatives or friends, and living in rented accommodation; unstable housing was defined as living in IDPs shelters, frequently changing accommodation, being homelessness and other housing types for example hostels and rehabilitation centres.

HCV genome sequencing

Although MinION based HCV sequencing methods have been described previously [20], we aimed to develop an alternative protocol that meets the clinical need for generation of near real-time sequencing data in field settings, without compromising sample integrity or losing sensitivity. Methods were adapted from the ARTIC Network nCoV-2019 Sequencing Protocol V3 LoCost (<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>). Briefly, we employed a 400 bp tiling amplicon scheme with genotype- and subtype-specific primers designed to generate partial or NFLG HCV sequences as per the Primal Scheme protocol using reference strains for HCV genotypes 1a, 1b, and 3a (see Supplementary Methods and Supplementary Tables 1 and 2). The obtained cDNA amplicons were purified, pooled, and used for library preparation with the Ligation Sequencing Kit (SQK-LSK109) (Oxford Nanopore Technologies, Oxford, UK). Final libraries were loaded onto a flow cell (FLO-MIN106) and sequenced with the MinION device. Consensus sequences from this study (Accession Numbers #) have been deposited into GenBank. All sequencing work was carried out in a simulated field environment using a “lab-in-a-suitcase” approach [18], hydroponic grow tents were implemented to physically separate pre-PCR, post-PCR, and master mix work to prevent sample contamination (Meredith et al., unpublished). Further details including bioinformatic workflow, beyond the description in this section, are presented in the Supplementary Materials.

Phylogenetics

HCV sequences were only included in further phylogenetic analysis if the obtained consensus sequence covered $\geq 50\%$ of the reference genome (sensitivity analyses were performed with other coverage levels and are presented in the Supplementary

materials). For each identified HCV subtype, all resulting consensus genome HCV sequences were aligned using the Muscle algorithm in AliView [21]. RaxML [22] was then used to reconstruct maximum likelihood (ML) phylogenetic trees for each subtype under a general time-reversible nucleotide substitution model with gamma-distributed rate-variation among sites (GTR+ Γ). We used ClusterPicker [23] to identify possible transmission clusters defined as clades with >90% bootstrap support and within-clades genetic distance <3%. Other previously published cluster-defining criteria were considered [14], but did not affect our findings (Supplementary Materials).

We used BEAST 1.10.4 [24] to perform molecular clock analyses and reconstruct population growth history for each of the identified HCV subtypes. We used the Bayesian Skyline population growth model (10 intervals), the GTR+ Γ nucleotide substitution model, and the uncorrelated lognormal relaxed clock model. Since our datasets did not have enough molecular clock signal (estimated by TempEst [25], Supplementary Table 4), we used previously published estimates for evolutionary rates of HCV subtypes to inform our analyses. Specifically, we used normally distributed priors with mean = 1.48E-3 and standard deviation = 2.3E-4, mean = 1.18E-3 and standard deviation = 2.1E-4, mean = 1.289E-3 and standard deviation = 1.47E-4, for subtypes 1a, 1b, and 3a, respectively [26, 27].

Results

Study population

A total of 164 IDPWID were recruited in Odessa, Ukraine, between June through September 2020 (Table 1). All participants had complete data, apart from one participant for the variable "previous HCV test results" which is indicated in Table 1. For each variable, cases with missing data were eliminated. Most participants identified as male (81.1%), completed secondary or higher education (73.2%), were single (46.9%), reported recent IDU (92.7%), and arrived in Odessa between 2014-2015 (53.7%). Six participants reported ever engaging in sex work and two participants reported men who have sex with men (MSM) contacts. The median participants' age was 37 years old (range 20 – 63) at the time of enrolment. The median length of IDU experience was 10 years (range 2 – 40).

Migration and IDU

Most IDPs were originally residing in the Donetsk region (51.2%) and migrated within a year of the beginning of the military conflict in April 2014 (69.5%). Most immediately settled in Odessa following migration (68.3%); of the rest, common regions for intermediate settlement prior to arrival in Odessa included Kyiv (28.8%) and Kharkiv (25%) amongst other locations across Ukraine, Russia, and Poland (Figure 2). For those who settled in Odessa immediately, the reported transit phase between leaving the region of origin and arriving to Odessa was two days or less, whilst for those who had settled elsewhere prior to arrival in Odessa, the median transit phase was 294 days (range 20 days - 5.5 years). In this study, 30.2% of IDPWID did not inject drugs prior to the conflict, of whom 14.8% reported starting IDU upon arrival to Odessa.

HIV and HCV prevalence

Previous HIV and HCV testing was reported by 91.5% and 84.1% of participants, respectively. Rapid testing identified seroprevalence of HIV, HCV, and HIV/HCV coinfection of 39%, 67.7%, and 31.1%, respectively. Of those who previously reported a positive HCV test (54.3%), 22.7% received treatment for HCV infection in the past. No participants reported COVID-19 symptoms (high temperature, a new cough, loss of taste or smell in the last 21 days) at the time of interview.

Migration and housing

The majority of IDPWID in our sample settled with relatives, friends, or in rented accommodation, both immediately following migration and at the time of the study in 2020 (50% and 60.4%, respectively). Of those residing in an IDPs shelter immediately following migration (11.6%), the median length of stay was seven months (range one month - six years). Over three times more participants reported homelessness (living on the street, in abandoned buildings, or train stations) in Odessa at the time of the study compared to immediately following migration (5.5% and 18.9%, respectively). There was no difference between those reporting stable (own house, staying with relatives/friends, or in a rented house) and unstable (staying in the IDPs shelter, changing accommodation frequently, or being homeless) housing at the time of study enrolment in terms of their HIV and HCV statuses (Supplementary Table 3). However, unstable housing amongst IDPWID at the time of the study enrolment was associated with IDU use in the last 30 days ($p=0.048$).

HCV sequencing data

Of the 164 people recruited, 90 samples resulted in PCR amplification producing 57 samples with partial (>50%) or NFLG sequences, and 33 samples with sequence coverage <50%. Samples with <50% coverage may be due to low sample quality, low viral loads, as well as low specificity of primer design and availability of reference genomes. These samples were not included for further analysis and future amplification methods will need to be adapted to improve amplification success rates. Of the samples that failed to amplify (74 or 45.1%), 35 were HCV antibody-negative by rapid test, and 39 were HCV antibody-positive; the latter may indicate successful treatment or spontaneously cleared infections. Of the 57 partial or NFLG HCV sequences generated (34.8% of the total 164 samples), genotypes 1a (N = 14), 1b (N = 23), and 3a (N = 20) were identified. Of these, 31 (54.4%) had previously tested positive for HCV but had not received treatment, and of whom five had received a positive anti-HCV test before moving to Odessa, which may indicate chronic infections or re-infection following spontaneous clearance. A total of four participants (7.0%) previously tested positive for HCV and received treatment in the past. Further treatment information would be necessary, which was unavailable in this study, to interpret whether the infection was not cleared, or whether this is a re-infection. At least 22 of these 57 participants were newly diagnosed with HCV in this study: 11 of

whom tested negative before and 11 were not tested before (although this does not take into consideration the four participants who received prior treatment as we were unable to distinguish re-infections).

HCV phylogenetics and phylodynamics

Phylogenetic trees were reconstructed separately for subtypes 1a, 1b, and 3a and included 14, 23, and 20 sequences, respectively (Figure 2). We identified three, four, and one potential transmission clusters (six clusters of two sequences, and two clusters of three sequences) on the subtype 1a, 1b, and 3a trees, respectively. Phylodynamic analysis showed that the time of most recent common ancestor (TMRCA) was in 1958 (95% Highest Posterior Density (HPD) 1915 - 1990), 1949 (1897 - 1983), and 1955 (1907 - 1992) for subtypes 1a, 1b, and 3a, respectively. The reconstructed Bayesian Skyline plots showed that the exponential growth of different HCV subtypes likely started in different decades (Figure 2), with subtype 1b growing before the 1990s, subtype 3a growing before the 2000s (coinciding with the HIV epidemic growth), and subtype 1a before the 2010s. The limited number of sequences in our analyses result in wide confidence intervals and prevent further interpretations of the past epidemic growth history. The TMRCAs for all subtype 1a clusters, subtype 1b cluster 6, and the 3a cluster dated pre-conflict and were estimated to be between 1987 and 2013, unlikely capturing a recent transmission event (Table 2 and Figure 3). Three of the subtype 1b clusters were more recent: TMRCAs for cluster 4, 5, and 7 were estimated to be in November 2011 (May 2005 – April 2016), May 2018 (August 2016 - October 2019), and December 2017 (October 2015 - May 2019), respectively.

Discussion

Here, we use Nanopore technology to obtain the first HCV genomes from Ukraine and show that Nanopore technology can be used to sequence HCV in a field simulated environment and that molecular clock analysis allows us to estimate timing of viral transmission events relative to the timing of forced migration. Specifically, we show evidence that HCV transmission events are likely to occur soon after arrival to the host region. Of the 57 participants from whom partial or NFLG HCV sequences were available, 29% were found in a total of eight potential infection clusters. Two of these clusters originated after members moved to Odessa: in both cases, the HCV transmission event happened within at most one and a half years upon arrival of the last individual to the city, suggesting that prevention efforts in long-term settlement environments will be beneficial soon after migration. In both of these recent clusters, although transmissions happened after migration, all cluster members originated from the same home regions (Donetsk and Crimea for clusters 4 and 7, respectively), which supports previous observations of the importance of social networks from the same home community post-migration amongst forcibly displaced people [28]. The clusters we identified are an underestimation of the true number of HCV transmissions in this group and are only indicative of transmission within the IDPWID community. Absence of other published HCV genomes from Ukraine made it impossible to compare clustering within and between migrant, home, and host communities.

Previous reports of genotype distribution in the general population in Ukraine in the early 2010s showed low prevalence of HCV infection with subtype 1a (1.6%), and a high prevalence of 1b (42.1%), followed by 3 (28.8%) [9]. In this study, we report much higher prevalence of HCV infection with the 1a (25%) subtype, and comparable levels of infection with 1b (40%) and 3a (35%) within IDPWID in Odessa. The HCV subtype 1b dominates epidemics in the neighboring Russian Federation (1a – 2.1%; 1b – 52.8%; 3 – 36.3%) and several post-Soviet countries, such as Uzbekistan and Azerbaijan, whilst 1a is more commonly found in western Europe [9, 29]. Higher 1a prevalence amongst HIV co-infected patients compared to the general population has been linked to IDU mediated transmission elsewhere [30], and thus is expected in our study population. The increase in 1a prevalence in our study, reflected in the most recent growth of this subtype compared to subtypes 1b and 3a as estimated by our

reconstructed Bayesian Skyline plots, follows the increase in HIV transmission in PWID [31].

Our results suggest that HCV seroprevalence in IDPWID currently residing in Odessa (67.7%) is now higher than the prevalence reported in 2015 in both autochthonous PWID (47.5%) and in PWID residing in Donetsk (55.2%) [10]. This may reflect our recruitment strategy, given the enhanced coupon distribution for HIV-positive participants who were not in ART treatment at the time of enrolment. Also, 22% of those receiving a positive anti-HCV test result had also received treatment in our study, compared to only 9.4% in a 2013 study, which may be due to a recent increase in targeted HCV treatment efforts for the PWID community [32, 33]. We generated four HCV genomes from IDPWID who previously received treatment, of which two were found in potential transmission clusters, likely indicating a re-infection or an incomplete treatment course. Continued engagement in treatment is crucial for transmission and disease progression prevention, but forcibly displaced people might face additional barriers in accessing these services [3, 4].

Due to a limited sample size, we were unable to link epidemiological data with our clusters, however we made important observations which can help inform targeted public health strategies. We report an increase in homelessness, an independent risk factor for HIV and HCV acquisition for PWID [6], at the time of the study (18.9%), compared to the period immediately following migration (5.5%). Most of those who lost their homes were residents of IDPs shelters or stayed with relatives/friends or rented their own accommodation upon arrival. Unstable housing at the time of the study was correlated with more IDPWIDs engaging in IDU in the last 30 days. We acknowledge the complexity of the categorisation of housing types in the literature, which may classify living with relatives/friends as unstable housing. In this study, we included the option of “frequently changing accommodation” which we believe may help encompass some of the hardships and risk factors faced when living with relatives/friends and which are characteristic of others in the unstable category. As such, the option of living with relatives/friends/rented was included in the stable category. Overall, IDPs are likely to reside in high-risk environments with limited prevention and treatment resources, thus long-term housing solutions for IDPs are likely to help minimise infection risks [4].

Many IDPWID in our sample initiated IDU after the beginning of the conflict (30.2%) or even after they migrated to Odessa (14.8%). Substance use amongst forcibly displaced people as a coping mechanism following conflict, violence, and migration stress is well documented in current literature [34]. In our study, two individuals who reported starting IDU after migration were found in HCV transmission clusters with those reporting 15 to 20 years IDU experience. Although IDPWID with prior experience of IDU may be more likely to seek and engage with harm reduction programs, efforts to inform and engage new injectors immediately following migration should be prioritised to reduce HCV transmission amongst this population.

Forced migration is a highly heterogenous and complex phenomenon, and is dependent on multiple factors including historical, economic, social, and political landscapes. The migration journey may differ across time: exposure to risk factors and hardships may continuously evolve. Regions with large migrant populations, limited laboratory capacities, and high prevalence of infectious diseases can especially benefit from the proposed integrative phylogenetic and epidemiological approach. Increased monitoring and understanding of the dynamics of infectious disease transmission networks, timing of transmission events, and risk factors unique to the experiences faced by forcibly displaced people is a crucial step in the development of effective health interventions.

Acknowledgements

We acknowledge the assistance of public health workers from the non-governmental organisations “Alliance of Public Health” and “Way Home” in collection of epidemiological and behavioural data and biological samples, and their ongoing efforts of providing preventative measures and infection management to at risk populations in Ukraine. We also express our sincere gratitude towards study participants. We thank Rowena Bull and Chaturaka Rodrigo for their advice with MinION based hepatitis C sequencing protocols. This work was funded by the John Fell Fund and the Wellcome Institutional Strategic Support Fund at the University of Oxford. TIV is supported by the Branco Weiss Fellowship. JOW is supported by an NIH-NIAID R01 (AI135992). Bioinformatics analyses reported herein were in part supported by an NIH NIGMS Institutional Development Award (IDeA), grant no. P20GM103395 (Alaska INBRE: Pathogenomics server – to E.B.). A.Y. was supported by a University of Cambridge BBSRC DTP studentship at the time of the study. IG is a Wellcome Senior Fellow. GK, LM, and IG are supported by grants from the Wellcome Trust (Refs: 207498/Z/17/Z and 206298/B/17/Z).

References

1. UNHCR, *Global Trends in Forced Displacement - 2020*. 2021.
2. RigAud, K., de Sherbinin, A., Jones, B., Bergmann, J., Clement, V., Ober, K., Schewe, J., Adamo, S., McCusker, B., Heuser, S., Midgley, A., *Groundswell: Preparing for Internal Climate Migration*. 2018.
3. Garry, S. and F. Checchi, *Armed conflict and public health: into the 21st century*. Journal of Public Health, 2020. **42**(3): p. e287-e298.
4. Ekezie, W., E.E. Adaji, and R.L. Murray, *Essential healthcare services provided to conflict-affected internally displaced populations in low and middle-income countries: A systematic review*. Health Promotion Perspectives, 2020. **10**(1): p. 24-37.
5. Pannetier, J., et al., *Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study*. The Lancet Public Health, 2018. **3**(1): p. e16-e23.
6. Arum, C., et al., *Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis*. Lancet Public Health, 2021. **6**(5): p. e309-e323.
7. UNHCR, *Registration of Internal Displacement in Ukraine*. 2021.
8. ECDPC, *HIV/AIDS Surveillance in Europe 2015*. 2016, European Centre for Disease Prevention and Control/WHO Regional Office for Europe: Stockholm, Sweden.
9. Blach, S., et al., *Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study*. The Lancet Gastroenterology & Hepatology, 2017. **2**(3): p. 161-176.
10. Barska, Y., Sazonova, Y., *Monitoring of behavior and HIV prevalence among people who use injecting drugs and their sexual partners*. 2016, Alliance for Public Health: Kyiv, Ukraine.
11. Chehl, N., et al., *HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics*. Medicine (Baltimore), 2019. **98**(28): p. e16242.
12. Luhmann, N., et al., *Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia*. International Journal of Drug Policy, 2015. **26**(11): p. 1081-1087.
13. Pybus, O.G. and A. Rambaut, *Evolutionary analysis of the dynamics of viral infectious disease*. Nat Rev Genet, 2009. **10**(8): p. 540-50.
14. Falade-Nwulia, O., et al., *Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore*. BMC Infectious Diseases, 2020. **20**(1): p. 815.
15. Bradshaw, D., et al., *Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England*. J Viral Hepat, 2020. **27**(7): p. 721-730.

16. Vasylyeva, T.I., et al., *Molecular epidemiology reveals the role of war in the spread of HIV in Ukraine*. Proceedings of the National Academy of Sciences, 2018. **115**(5): p. 1051-1056.
17. Quick, J., et al., *Real-time, portable genome sequencing for Ebola surveillance*. Nature, 2016. **530**(7589): p. 228-232.
18. Brunker, K., et al., *Rapid in-country sequencing of whole virus genomes to inform rabies elimination programmes [version 2; peer review: 3 approved]*. Wellcome Open Research, 2020. **5**(3).
19. DD, H., *Respondent-Driven Sampling: A New Approach to the Study of Hidden Populations*. Social Problems, 1997. **44**(2): p. 174-199.
20. Riaz, N., et al., *Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants*. BMC Genomics, 2021. **22**(1): p. 148.
21. Larsson, A., *AliView: a fast and lightweight alignment viewer and editor for large datasets*. Bioinformatics, 2014. **30**(22): p. 3276-8.
22. Stamatakis, A., *RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies*. Bioinformatics, 2014. **30**(9): p. 1312-3.
23. Ragonnet-Cronin, M., et al., *Automated analysis of phylogenetic clusters*. BMC Bioinformatics, 2013. **14**: p. 317.
24. Suchard, M.A., et al., *Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10*. Virus Evol, 2018. **4**(1): p. vey016.
25. Rambaut, A., et al., *Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen)*. Virus Evolution, 2016. **2**(1).
26. Gray, R.R., et al., *The mode and tempo of hepatitis C virus evolution within and among hosts*. BMC Evolutionary Biology, 2011. **11**.
27. Li, C., et al., *Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e*. J Gen Virol, 2014. **95**(Pt 8): p. 1677-1688.
28. Bilecen, B., M. Gamper, and M.J. Lubbers, *The missing link: Social network analysis in migration and transnationalism*. Social Networks, 2018. **53**: p. 1-3.
29. Hostager, R., et al., *Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage*. Virus Evol, 2019. **5**(2): p. vez041.
30. Isakov, V., et al., *Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia*. International Journal of Infectious Diseases, 2021. **113**: p. 36-42.
31. Vasylyeva, T.I., et al., *Reducing HIV infection in people who inject drugs is impossible without targeting recently-infected subjects*. Aids, 2016. **30**(18): p. 2885-2890.

32. Salyuk, T. and I. Sazonova, *Current challenges associated with hepatitis C virus (HCV) among people who inject drugs (PWID) in Ukraine*. Journal of Clinical Virology, 2015. **69**: p. 237-237.
33. Mazhnaya, A., et al., *Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes*. The International journal on drug policy, 2017. **47**: p. 187-195.
34. Horyniak, D., et al., *Epidemiology of Substance Use among Forced Migrants: A Global Systematic Review*. PLOS ONE, 2016. **11**(7): p. e0159134.

Figures and Tables




Figure 1

Recruitment flow diagram. IDU – injection drug use, ART – anti-retroviral treatment, IDPs – internally displaced persons, IDPWID – internally displaced people who inject drugs.




Figure 2 Legend continued on the next page.

Figure 2

A – Map of Ukraine illustrating migration journeys. Beige colour indicates regions that were often a place of settlement prior to arrival to Odessa.

B – Maximum Likelihood phylogenetic trees reconstructed for each HCV genotype and phylogenetic clusters marked on the trees. Tree tips colours correspond to the home regions of IDPWID. Scale bars indicate substitutions/site/year.

C – Bayesian Skyline plots reflecting effective population size over time estimated for each of the identified HCV subtypes (red horizontal line – median, black horizontal lines – 95% HPD). Black dotted lines represent the median and lower 95% HPD bound of the time to most recent common ancestor for each subtype. Y-axis indicates log effective population size.




Figure 3

TMRCA uncertainties for HCV phylogenetic clusters in relation to conflict and migration timings. Green indicates TMRCA and black bars are 95% HPD. Purple circle indicates time of latest IDPWID arrival to Odessa within that cluster. Red dashed line indicates the start of the conflict.

Table 1 – Characteristics of IDPWID recruited in Odessa in 2020

Part 1. Sociodemographic characteristics			
		N	%
Sex	Male	133	81.1
	Female	31	18.9
Age (years), median (range)	37 (20-63)		
Age (years)	20-29	20	12.2
	30-39	78	47.6
	40-49	51	31.1
	50-63	15	9.1
Other risk behaviours	Sex work	6	3.7
	MSM contacts	2	1.2
Duration of IDU (years)	2 to 10	86	53.1
	11 to 20	54	33.3
	21 to 30	19	11.7
	31 to 40	3	1.9
IDU in the past 30 days	Yes	152	93.8
	No	10	6.2
Education	Nine or less school years	44	26.8
	High School	54	32.9
	Technical School	52	31.7
	University Degree	13	7.9
	Other	1	0.6
Marital Status	Married	23	14.0
	Living with sexual partner	40	24.4
	Single	77	47.0
	Divorced or widowed	23	14.0
	Other	1	0.6

Part 2. Migration information			
		N	%
Home region	Crimea	35	21.3
	Donetsk	84	51.2
	Lugansk	45	27.4
Alternative settlement prior to arrival in Odessa	Yes, resided in another region	52	31.7
	No, settled in Odessa immediately	112	68.3
Settlement prior to arrival to Odessa	Kyiv	15	28.8
	Kharkiv	13	25.0
	Other (Ukraine, Russia, Poland)	24	46.2
Duration of transit phase (days), median (range)	294 (20 - 2005)		
Arrival to Odessa	2014-2015	88	53.7
	2016-2020	76	46.3
IDU initiation	Prior to conflict	113	69.8
	After conflict	49	30.2
IDU initiation	Prior to migration	138	85.2
	After migration	24	14.8
Housing (immediately following migration)	Own house or flat	13	7.9
	With relatives/friends/rented	99	60.4
	Shelter for IDPs	19	11.6
	Frequently changed	20	12.2
	Homeless (living on the street, in abandoned buildings, or train stations)	9	5.5
	Other (incl. hostel, rehabilitation centre)	4	2.4
Length of stay in IDPs shelter (months), median (range)	7.1 (1-72)		
Housing (now)	Own house or flat	18	11.0
	With relatives/friends/rented	82	50.0
	Shelter for IDPs	12	7.3
	Frequently changed	19	11.6
	Homeless	31	18.9
	Other	2	1.2

Part 3. Medical information			
		N	%
Rapid Test HIV	Positive	64	39.0
	Negative	100	61.0
Previous HCV test	Yes	138	84.1
	No	26	15.9
Previous HCV test result	Positive	75	54.3
	Negative	62	44.9
	Unknown	1	0.7
Previous HCV treatment	Yes	17	22.7
	No	58	77.3
Rapid Test HCV	Positive	111	67.7
	Negative	53	32.3
Rapid Test HCV/HIV	Coinfected	51	31.1

Table 2 – Cluster composition and time to the most recent common ancestor (TMRCA) for HCV phylogenetic clusters

Subtype	Cluster	Number of sequences	TMRCA	TMRCA 95% HPD	Time of IDPWID arrival to Odessa	Home region	Rapid HIV test result
1a	1	3	1998	1982 - 2009	2014, 2014, 2016	Lugansk, Donetsk, Crimea	Pos, Pos, Pos
	2	2	2005	1993 - 2013	2015, 2017	Donetsk, Donetsk	Pos, Neg
	3	2	2000	1984 - 2011	2016, 2015	Donetsk, Lugansk	Pos, Pos
1b	4	2	Nov 2011	May 2005 - April 2016	May 2015, Jun 2015	Lugansk, Donetsk	Pos, Pos
	5	2	May 2018	Aug 2016 - Oct 2019	Aug 2014, Mar 2018	Donetsk, Donetsk	Pos, Pos
	6	2	1999	1982 - 2010	2018, 2017	Lugansk, Crimea	Neg, Neg
	7	3	Dec 2017	Oct 2015 - May 2019	Jun 2015, Sep 2017, Oct 2015	Crimea, Crimea, Crimea	Neg, Neg, Neg
3a	8	2	1987	1961 - 2004	2018, 2018	Crimea, Donetsk	Neg, Pos

Supplementary Methods

Study Design and Data Collection

Participants were interviewed by social workers from the non-governmental organisation “Way Home”. At the time of interview, all participants were screened for HIV and HCV using Wondfo® One Step HIV1/2 Whole Blood/Serum/Plasma and Wondfo® One Step HCV Whole Blood/Serum/Plasma.

RNA Extraction and cDNA Synthesis

Viral RNA was extracted from 140 µL serum using QIAamp Viral RNA Minikit (Qiagen), following the manufacturer’s instructions. Extracted RNA was eluted in a 60 µL volume, aliquoted and stored until use at –80°C. Extracted RNA was reverse transcribed using SuperScript IV Reverse Transcriptase (SSIV RT, ThermoFisher Scientific). Each reaction included 1 µL random hexamers (ThermoFisher Scientific), 1 µL 10 mM dNTP (ThermoFisher Scientific), 3 µL SSIV buffer, 0.5 µL 0.1M DTT, 0.5 µL RNaseOUT (ThermoFisher Scientific), 0.5 µL SSIV RT and 6.5 µL RNA extract. The mix was incubated at 23°C for 10 min, 50°C for 50 min, 75°C for 10 min, and then held at 4°C.

Primer Design

To amplify and sequence low abundance viruses directly from the clinical samples we employed a tiling amplicon scheme with the genotype- and subtype-specific primers. Primers were designed to generate near full length HCV genome sequences as per the Primal Scheme (<https://primalscheme.com>) protocol based on multiplex tiling PCR amplification of 400bp amplicons overlapping neighbouring amplicons by 75 nt [1]. A collection of reference strains for HCV genotypes 1a, 1b, and 3a were identified based on closest available geographical and temporal sequences from GenBank (Supplementary Table 1). Primers for each genotype were pooled into 100 µM pool A and B stock mixes based on alternate regions, which do not overlap within the same pool (Supplementary Table 2).

PCR Amplification

HCV PCR amplification and sequencing methods were adapted from the ARTIC Network nCoV-2019 Sequencing Protocol V3 LoCost

(<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>).

Briefly, PCR amplifications were performed using Q5 Hot Start High-Fidelity DNA Polymerase (NEB). Two separate reactions for primer pool A and B were prepared in a final volume of 12.5 μ L, containing 2.5 μ L 5X Q5 Reaction Buffer, 0.25 μ L Q5 Hot Start DNA Polymerase, 10 μ M primer pool (A or B), 0.5 μ L 10 mM dNTPs, 3.75 μ L nuclease-free water and 3.75 μ L cDNA template. Thermocycling was performed using a mini16 thermal cycler (minipcr) with the following program: 98°C for 30 secs, then 35 cycles of 98°C for 15 secs, 62.5°C for 5 min, and final hold at 4°C. Pool A and B reaction products for a given sample were pooled together in equal volumes and quantified QuantiFluor® ONE dsDNA Dye (Promega) using the Quantus Fluorometer (Promega).

Oxford Nanopore Library Preparation and Sequencing

Samples were purified with SPRI beads (x1 ratio) and eluted in 25 μ L of nuclease-free water. Amplicon ends were prepared for ligation with the NEBNext Ultra II End Repair/dA-Tailing Module (NEB). Unique barcodes from the Oxford Nanopore Native Barcoding Expansion kits EXP-NBD104 (1-12) and EXP-NBD114 (13-24) were ligated to each sample using the NEBNext Ultra II Ligation Module (NEB). Following barcoding, reactions were pooled together in equal volumes and purified with SPRI beads (x0.4 ratio). Finally, Oxford Nanopore sequencing adapters were ligated with the NEBNext Quick Ligation Module (NEB) and the library was purified with SPRI beads again (x1 ratio) and quantified using the Quantus Fluorometer (Promega). Final libraries were loaded onto a flow cell (FLO-MIN106) and sequenced with the MinION.

Bioinformatic Workflow

All runs were basecalled using guppy basecaller 4.4.2 with the high accuracy model. Demultiplexing was performed as a separate step with guppy barcoder using additional arguments to detect mid strand barcodes. During the demultiplexing step barcodes and an additional 25nt were trimmed from the reads to remove primers. Reads were aligned to 54 HCV reference genomes with Minimap2 [2] and the reference with the highest number of primary mappings as determined by samtools [3] was used as a draft genome for a reference guided assembly. Racon 1.4.21 [4] was used to polish the reference genome with the no trim argument enabled and window size set to 300nt. The draft generated by racon was then polished with medaka

consensus (<https://github.com/nanoporetech/medaka>) and any nucleotides with less than 20x coverage were masked. To test for the presence of multiple genomes within the sample, reads that mapped to the previously generated assembly were removed and the remaining reads were again aligned to the 54 reference genomes. Barcodes with over 200k reads mapped to a second genome were used to generate additional assemblies.

Sensitivity analysis

Previously published cluster-defining criteria were considered [5, 6]. For subtype 1a analysis, the number of identified clusters was the same if the genetic distance threshold ranged between 3-6%. If the bootstrap support was relaxed to 80 instead of 90 and genetic distance threshold was considered at 4.5%, then 1 additional cluster of 4 sequences was identified. For subtypes 1b and 3a analyses, the same clusters were identified with genetic distance threshold varying 3-6% and bootstrap support of 80.

References

1. Quick, J., et al., *Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples*. Nature protocols, 2017. **12**(6): p. 1261-1276.
2. Li, H., *Minimap2: pairwise alignment for nucleotide sequences*. Bioinformatics, 2018. **34**(18): p. 3094-3100.
3. Li, H., et al., *The Sequence Alignment/Map format and SAMtools*. Bioinformatics, 2009. **25**(16): p. 2078-2079.
4. Vaser, R., et al., *Fast and accurate de novo genome assembly from long uncorrected reads*. Genome Res, 2017. **27**(5): p. 737-746.
5. Falade-Nwulia, O., et al., *Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore*. BMC Infectious Diseases, 2020. **20**(1): p. 815.
6. Bradshaw, D., et al., *Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England*. Journal of Viral Hepatitis, 2020. **27**(7): p. 721-730.

Supplementary Tables

Supplementary Table 1 – Accession numbers for reference genomes used for HCV primer design

Genotype	Accession number	Genotype	Accession number
1a	EU260395	1b	GU451218
1a	D10749	3a	AB792683
1a	KC844049	3a	KC844041
1a	EU482876	3a	MG428679
1a	EU256050	3a	GQ275355
1a	EU239715	3b	KC844044
1a	EU256033	3a	JQ717258
1a	EU256027	3a	JQ717256
1a	EU239713	3a	JQ717259
1a	EU256040	3a	JN714194
1a	EU255932	3a	KF035123
1a	EU155310	3a	KF035127
1a	EU155287	3a	KF035126
1a	EU255951	3a	KF035124
1a	EU256048	3a	JQ717260
1a	EU256097	3a	JQ717254
1a	EU155275	3a	JQ717257
1a	EU155239	3a	JQ717255
1a	EU781746	3a	KF035125
1a	EU256105		
1a	NC_004102		
1b	AB435162		
1b	AF139594		
1b	AB049088		
1b	DQ071885		
1b	AJ238799		
1b	KC844051		
1b	EU857431		
1b	AF176573		
1b	KC844052		
1b	AB049101		
1b	AB249644		
1b	EF032892		
1b	GU451224		
1b	GU451223		
1b	GU451222		
1b	GU451221		
1b	GU451220		
1b	GU451219		

1b	GU451218		
3a	AB792683		
3a	KC844041		

Supplementary Table 2 – HCV Sequencing Primers

Primer Name	Sequence
HCV-400-1a_1_LEFT	GTATGAGTGTCTGCAGCCT
HCV-400-1a_1_RIGHT	GCTCGGAAGTCTTCCTCGTC
HCV-400-1a_2_LEFT	CGGTCAGATCGTTGGTGGAG
HCV-400-1a_2_RIGHT	TTCACGCCGTCTTCCAGAAC
HCV-400-1a_3_LEFT	GCCGACCTCATGGGGTACAT
HCV-400-1a_3_RIGHT	CGCTCCCGACAAGCAGATC
HCV-400-1a_4_LEFT	GCCTACCAAGTGCGCAACTC
HCV-400-1a_4_RIGHT	GGACCAGTTCATCATCATATCCCA
HCV-400-1a_5_LEFT	AGCGTATTTCTCCATGGTGGG
HCV-400-1a_5_RIGHT	TAGTGCCAGCAGTAGGGGC
HCV-400-1a_6_LEFT	TGCTATTTGCCGCGTCG
HCV-400-1a_6_RIGHT	TGAAGCAATATACTGGGCCACA
HCV-400-1a_7_LEFT	TTCACTCCCAGCCCCGT
HCV-400-1a_7_RIGHT	CTTCCAGCCTGTGCTCGAC
HCV-400-1a_8_LEFT	GGCTCCGGTCCCTGGATTAC
HCV-400-1a_8_RIGHT	CACAAGCAGGAGCAGACGC
HCV-400-1a_9_LEFT	CCTGGGCCATCAAGTGGGA
HCV-400-1a_9_RIGHT	AGCCACCATAAGCACCAGC
HCV-400-1a_10_LEFT	TGTGGCGCGTTGTTCTTG
HCV-400-1a_10_RIGHT	GTGCCAGTAAGCGCCCCTA
HCV-400-1a_11_LEFT	GCTAGCGCGGAAAATGGC
HCV-400-1a_11_RIGHT	GGTTTTGTCCCGGCCAGT
HCV-400-1a_12_LEFT	AAGGGGTGGAGGTTGCTGG
HCV-400-1a_12_RIGHT	AATGGGCCGGGGCGAAA
HCV-400-1a_13_LEFT	CGGCTCCTCGGACCTTTAC
HCV-400-1a_13_RIGHT	GGTTGAGCACCAGCACCTT
HCV-400-1a_14_LEFT	GCATGCTCCACAGGCA
HCV-400-1a_14_RIGHT	ACCTCCTCGATGTTAGGATGGG
HCV-400-1a_15_LEFT	GTCCTTGACCAAGCAGAGACTG
HCV-400-1a_15_RIGHT	GGGTCAAGGCTGAAATCGACT
HCV-400-1a_16_LEFT	GGCTTTACCGGCGACTTCG
HCV-400-1a_16_RIGHT	TCTGGGATAGGAAGTGGGCAT
HCV-400-1a_17_LEFT	ATGAACACCCCGGGGCTTC
HCV-400-1a_17_RIGHT	GACCACGCAGCCTGTTGA
HCV-400-1a_18_LEFT	ACCTGGAGGTCGTCACGAG
HCV-400-1a_18_RIGHT	CCAGGCAACGTTGACAGACC
HCV-400-1a_19_LEFT	TCCCGTCAGGCAGAGGTTAT
HCV-400-1a_19_RIGHT	GGGACCTCACCGCTCATGAT
HCV-400-1a_20_LEFT	GTTGGACTGGGGAAGGTCCT

HCV-400-1a_20_RIGHT	CAGGAACCGGAGCATGGAGT
HCV-400-1a_21_LEFT	CAGCAGCCTCACTGTAACCC
HCV-400-1a_21_RIGHT	ACCCTCCACAGCGCGAA
HCV-400-1a_22_LEFT	AGGATCGTCGGTCTTAGGAC
HCV-400-1a_22_RIGHT	GGATCAGTGAGCATGGACGT
HCV-400-1a_23_LEFT	GACTCCACGAGTACCCGGT
HCV-400-1a_23_RIGHT	GGGCGAATCTCCGAGACTTC
HCV-400-1a_24_LEFT	CGCCGAGCTCATAGAGGCTA
HCV-400-1a_24_RIGHT	GGAAGTTGAGGAGCTGCCAA
HCV-400-1a_25_LEFT	GAAGAAGCGGACGGTGGTC
HCV-400-1a_25_RIGHT	ACTGCGTGAGGTGGTGGAAAT
HCV-400-1a_26_LEFT	TGCGCCGCGGAAGAACA
HCV-400-1a_26_RIGHT	CTCAGGCTGAACGCAGAAAAC
HCV-400-1a_27_LEFT	CCGTGTGGAAAGACCTTCTGG
HCV-400-1a_27_RIGHT	GGACTTGATGGCCACACGG
HCV-400-1a_28_LEFT	TCCACAGTCACTGAGAGCGA
HCV-400-1a_28_RIGHT	TGATGTTATGAGCTCCAAGTCGT
HCV-400-1a_29_LEFT	TCACGGAGGCTATGACCAGG
HCV-400-1a_29_RIGHT	AGGCCATGGAGTCTTTGAATGA
HCV-400-1a_30_LEFT	GCCAGGGATCAGCTTGAACA
HCV-400-1a_30_RIGHT	GGCATGAGACACGCTGTGAT
HCV-400-1b_1_LEFT	AGGAACTACTGTCTTCACGCAG
HCV-400-1b_1_RIGHT	CGCGGCAACAGGTAAACTCC
HCV-400-1b_2_LEFT	CCAAACGTAACACCAACCGC
HCV-400-1b_2_RIGHT	CGAGCGGAATGTACCCCATG
HCV-400-1b_3_LEFT	GCCCCTCTATGGCAATGAGG
HCV-400-1b_3_RIGHT	GTCCGCTGCCTCATAACAA
HCV-400-1b_4_LEFT	GTGTCCGGGTTCTGGAGGA
HCV-400-1b_4_RIGHT	GATCCGCAGAGATCCCCCA
HCV-400-1b_5_LEFT	ATCTCTGCGGATCTGTTTTCT
HCV-400-1b_5_RIGHT	CCGTTGGTGTTTACAAGCTGGA
HCV-400-1b_6_LEFT	GGGAACTGGGCTAAGGTTCTG
HCV-400-1b_6_RIGHT	ACCACACACCTGCGACG
HCV-400-1b_7_LEFT	GGAAGTCCCTGAACTGCAA
HCV-400-1b_7_RIGHT	ACGTCTTGGTGAACCCAGTG
HCV-400-1b_8_LEFT	CTGGTTCGGCTGTACATGGA
HCV-400-1b_8_RIGHT	GGTAGGGTGGTGAAGGAACAG
HCV-400-1b_9_LEFT	CTCTGGCACTACCCCTGCA
HCV-400-1b_9_RIGHT	TGGGCTATCAGCAGCATCATC
HCV-400-1b_10_LEFT	GGGTCAGCGGTTGTCTCCTT
HCV-400-1b_10_RIGHT	ACCATATGAGCCTAGCGAGGA
HCV-400-1b_11_LEFT	ACCGGGAGATGGCTGCATC

HCV-400-1b_11_RIGHT	TCAGTGCGGCCAGCTTCA
HCV-400-1b_12_LEFT	TCCGTGCATGCATGTTGGT
HCV-400-1b_12_RIGHT	TCGACCTGGTTCTTGTCCCG
HCV-400-1b_13_LEFT	AGGCACGTACGTTTATGACCA
HCV-400-1b_13_RIGHT	GTCCAACACACGCCGTTGA
HCV-400-1b_14_LEFT	CGCAACACAATCTTTCCTGGC
HCV-400-1b_14_RIGHT	AAGTCCACCGCCTTCGC
HCV-400-1b_15_LEFT	TCTTCGGGTGGTCCACTGC
HCV-400-1b_15_RIGHT	AGGAACTTGCCGTAGGTGGA
HCV-400-1b_16_LEFT	CCAAGGGTACAAGGTGCTCG
HCV-400-1b_16_RIGHT	CTCGATGGGGATGGCTTTGC
HCV-400-1b_17_LEFT	CTTGTCGTGCTCGCTACCG
HCV-400-1b_17_RIGHT	CGGTGCTGCTCAATGGTG
HCV-400-1b_18_LEFT	TGATCGACTGTAACACATGTGTCA
HCV-400-1b_18_RIGHT	GGGAAGTTGTCTCCTGCCTG
HCV-400-1b_19_LEFT	GTTGCCCGTTTGCCAGGAC
HCV-400-1b_19_RIGHT	CCACAATGACCACGCTGCC
HCV-400-1b_20_LEFT	CCCCTGCTGTATAGGCTAGGA
HCV-400-1b_20_RIGHT	CCAATTGGACTCCACCACG
HCV-400-1b_21_LEFT	GGAATGCAGCTCGCCGA
HCV-400-1b_21_RIGHT	AGATGTCCACAAGCACCTTCC
HCV-400-1b_22_LEFT	ACCCTCCTGTTAACATCTTGGG
HCV-400-1b_22_RIGHT	CGTCGCTCTCAGGCACATAG
HCV-400-1b_23_LEFT	CAGTGGATGAACCGGCTGAT
HCV-400-1b_23_RIGHT	ACGATCCTCATGGAACCGTTTT
HCV-400-1b_24_LEFT	TGACTGACTTCAAGACCTGGC
HCV-400-1b_24_RIGHT	GAACCTGGCATGGGCACT
HCV-400-1b_25_LEFT	GCTGAGGAGTACGTGGAGGT
HCV-400-1b_25_RIGHT	GGGTAGTGCATGTCGCCTTC
HCV-400-1b_26_LEFT	GGTTGCACAGGTACGCTCC
HCV-400-1b_26_RIGHT	TCATCCTCCTCCGCTCGAA
HCV-400-1b_27_LEFT	TTCGAGCGGAGGAGGATGA
HCV-400-1b_27_RIGHT	CAAGGGGAGGCATGGAGGA
HCV-400-1b_28_LEFT	GAGCTCGCCACAAAGACCTT
HCV-400-1b_28_RIGHT	CCAGGACTTGCAGTCTGTCAA
HCV-400-1b_29_LEFT	TGCTGCGTCACCACAACATG
HCV-400-1b_29_RIGHT	CCAAGTCTGGGAATACGATAAGGC
HCV-400-1b_30_LEFT	TGGAAGACACTGAGACACCAATT
HCV-400-1b_30_RIGHT	CCCCGATATAAAGCCGCTCTG
HCV-400-1b_31_LEFT	GAGGAGTCAATTTACCAATGTTGTGAC
HCV-400-1b_31_RIGHT	GCGACCGACACATTGGAGG
HCV-400-1b_32_LEFT	ACGGAGGCTATGACTAGGTACTC

HCV-400-1b_32_RIGHT	GGAGTGAAAATGCGCTAAGACC
HCV-400-1b_33_LEFT	GTCAGATCTACGGGGCCTGT
HCV-400-1b_33_RIGHT	GAAAGTAGGAGTAGGCACCACA
HCV-400-3_1_LEFT	GAGGCGACACTCCACCATG
HCV-400-3_1_RIGHT	CGGGAACCTGACGTCTGTG
HCV-400-3_2_LEFT	TGCAACATGAGCACACTTCCT
HCV-400-3_2_RIGHT	CCCATGAGGTCGGCGAATC
HCV-400-3_3_LEFT	ACGATTGGGTGTGCGCG
HCV-400-3_3_RIGHT	AGATAGAAAAGGAGCAACCGGG
HCV-400-3_4_LEFT	GGGAATTTGCCCGTTGCT
HCV-400-3_4_RIGHT	GGGTCTGAACGTGAAGGCTT
HCV-400-3_5_LEFT	TGGACCCAGTGACACCTAC
HCV-400-3_5_RIGHT	TTGGCCCAGTTACCCTGCAT
HCV-400-3_6_LEFT	GTCCAGACCTGCAACTGCTC
HCV-400-3_6_RIGHT	AGCTAAGAACCCGGTGTTTATGG
HCV-400-3_7_LEFT	GGCTCGTGGCACATCAACAG
HCV-400-3_7_RIGHT	CACCCAAACCACCGACCAC
HCV-400-3_8_LEFT	TTCACACCATCGCCAGTGG
HCV-400-3_8_RIGHT	CCCACGAACATCCTCACCTT
HCV-400-3_9_LEFT	AAGGTGAGGATGTTCGTGGG
HCV-400-3_9_RIGHT	AGCAGCGACGGCGTTCA
HCV-400-3_10_LEFT	CCTCGTCTTCCTCCTCTGG
HCV-400-3_10_RIGHT	ATGGCGTACTGGTTCCACCA
HCV-400-3_11_LEFT	ACGGGTCTTTGGTCCCTAGC
HCV-400-3_11_RIGHT	ACGAGCATGCAAAGGCGAA
HCV-400-3_12_LEFT	TGACATCACCAAGCTGCTGA
HCV-400-3_12_RIGHT	CGCCAACCCATCTCCCGATA
HCV-400-3_13_LEFT	AGTCCCATGGAAATCAAGGTCA
HCV-400-3_13_RIGHT	CTGGCCACCCAACGAGATC
HCV-400-3_14_LEFT	GGTACAACAGTGGGAGGGGT
HCV-400-3_14_RIGHT	CCTAGCCTGTGTGCTAAGGG
HCV-400-3_15_LEFT	GCTGTGTGCACCAGAGGT
HCV-400-3_15_RIGHT	ACATCATATGCTCCCCCGGA
HCV-400-3_16_LEFT	GGCTTCGGCGCTTTCATG
HCV-400-3_16_RIGHT	AGGTGCCTCCCTCCCTTGA
HCV-400-3_17_LEFT	ACTGTGCCACATTCTAACATCGA
HCV-400-3_17_RIGHT	ACGTTGGCTGCGGGAAAC
HCV-400-3_18_LEFT	TTGAACAGTACGTTGACTTCAGC
HCV-400-3_18_RIGHT	CGCACACAGTGGCTTGGTA
HCV-400-3_19_LEFT	TGCCACTTTCTGTACAGAC
HCV-400-3_19_RIGHT	CACCTCTTTGTCTGGAACGAGT
HCV-400-3_20_LEFT	GCGGCCTACTGCTTGTGAC

HCV-400-3_20_RIGHT	TGGTTGGTTGTCAGGGGACT
HCV-400-3_21_LEFT	TGCCTGGCAACCCTGCT
HCV-400-3_21_RIGHT	TCCCAGGTCCTACGTGTC
HCV-400-3_22_LEFT	ATGGTCAACCTATTGCCCGC
HCV-400-3_22_RIGHT	CCTTTTGACAGGAAATAAAGGGCAG
HCV-400-3_23_LEFT	TACCCAAGTCCTTGCAGCGG
HCV-400-3_23_RIGHT	GTGATGTAATGGAAATCCCCCAC
HCV-400-3_24_LEFT	CCCAACTACACTCGCGCAC
HCV-400-3_24_RIGHT	TGGCTGGCGGATGAGCT
HCV-400-3_25_LEFT	TGTGCTGACCTCGATGTTGAG
HCV-400-3_25_RIGHT	GCTTCCAGCGGTCCAACA
HCV-400-3_26_LEFT	GTGTTTCAAGAAACCTCCCAAGT
HCV-400-3_26_RIGHT	GAGTCGCAGCTCAAGTCTGG
HCV-400-3_27_LEFT	AGGAAGAGAACAATCCAGCTGG
HCV-400-3_27_RIGHT	AGACGACGTTGAATAGACTAGGTT
HCV-400-3_28_LEFT	GGCGCCCTGATAACACCATG
HCV-400-3_28_RIGHT	TTCGCCATGATGGTGGTTGG
HCV-400-3_29_LEFT	GTTCGCTCCTTGCCAGCAA
HCV-400-3_29_RIGHT	ACAGCATTGGTATATCTCCTCTTCC
HCV-400-3_30_LEFT	TCGTATGACACCCGCTGCT
HCV-400-3_30_RIGHT	ACCTGGTCATAGCCTCCGTG
HCV-400-3_31_LEFT	TGGTCGTGGTGGCAGAGAG
HCV-400-3_31_RIGHT	ACAGAGTAAGTGGCCCCGTA
HCV-400-3_32_LEFT	GGTGCGCATGGTAATGATGAC
HCV-400-3_32_RIGHT	GCCAACCGTAAACCAGCTGG
HCV-400-3_33_LEFT	ACCAGCAATCATTGAAAGACTCCA
HCV-400-3_33_RIGHT	TCACCGAGCTGGCAGGA

Supplementary Table 3 – Characteristics of participants based on their housing situation at the time of study enrolment

		Housing		
		Stable	Unstable	Chi-square p-value
HIV test result	Positive	34	30	0.1
	Negative	66	34	
HCV test result	Positive	71	40	0.26
	Negative	29	24	
IDU in the past 30 days	Yes	89	63	0.048
	No	9	1	

Supplementary Table 4 – Results of the TempEst analysis

Dataset	Root-to-tip correlation coefficient	Estimated evolutionary rate	Prior for clock rate
1a	0.09	0.02	0.00148 (2.3E-4)
1b	0.19	0.02	0.00118 (2.1E-4)
3a	-0.12	-0.02	0.001289 (1.47E-4)

Supplementary Table 5 – Accession numbers of reference genomes used for HCV genome assembly

AB030907.1	AF356827.1	D84264.2	KY620617.1
AB031663.1	AJ851228.1	D84265.2	KY620631.1
AB047639.1	AY051292.1	D90208.1	KY620719.1
AB047641.1	AY232730.1	DQ155561.1	LC368440.1
AB049088.1	D00944.1	EU155324.2	MH742369.1
AB435162.2	D10988.1	EU155378.2	MT512570.1
AB792683.1	D14853.1	EU256065.1	Y11604.1
AF009606.1	D17763.1	EU260395.1	Y12083.1
AF011751.1	D28917.1	EU482858.1	Y13184.1
AF046866.1	D49374.1	KT983617.1	
AF064490.1	D50409.1	KX767055.1	
AF139594.2	D63821.1	KY620523.1	
AF169004.1	D63822.1	KY620603.1	
AF238486.1	D84262.2	KY620604.1	
AF271632.1	D84263.2	KY620616.1	